Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis

Molecular and Cellular Biology

Volumn 21, Issue 22, 2001, Pages 7653-7662

  Eischen, C M ^a   Roussel, M F ^a   Korsmeyer, S J ^a   Cleveland, J L ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BAX; PROTEIN MDM2; PROTEIN P53;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; DOSE RESPONSE; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; LYMPHOMA; NONHUMAN; ONCOGENE MYC; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN DEPLETION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; B-LYMPHOCYTES; BCL-2-ASSOCIATED X PROTEIN; CELLS, CULTURED; LYMPHOMA, B-CELL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MUTAGENESIS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; DROMAIUS NOVAEHOLLANDIAE; MUS MUSCULUS;

EID: 0034775395     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.21.22.7653-7662.2001     Document Type: Article

References (63)

1. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
2. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis
3. Mdm2 expression is induced by wild-type p53 activity
4. BAX frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability
5. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis
6. Apoptosis triggered by Myc-induced suppression of Bcl-XL or Bcl2 is bypassed during lymphomagenesis
7. Induction of apoptosis in fibroblasts by c-myc protein
8. Cooperative interaction between c-myc and bcl-2 proto-oncogenes
9. BCL-2 family members and the mitochondria in apoptosis
10. The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein
11. p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts
12. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
13. Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1
14. Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution
15. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers
16. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus
17. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF
18. The tumorigenic potential and cell growth characteristics of p53- deficient cells are equivalent in the presence or absence of Mdm2
19. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF
20. Bax accelerates tumorigenesis in p53-deficient mice
21. Bcl-2 and Bax function independently to regulate cell death
22. Bax-deficient mice with lymphoid hyperplasia and male germ cell death
23. BCL-2 gene family and the regulation of programmed cell death
24. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues
25. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins
26. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53
27. Twist is a potential oncogene that inhibits apoptosis
28. Bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis
29. Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice
30. Hematopoietic malignancies demonstrate loss-of-function mutations of BAX
31. Bax mutations in cell lines derived from hematological malignancies
32. Bax is a transcriptional target and mediator of c-myc-induced apoptosis
33. Identification of a p53-dependent negative response element in the bcl-2 gene
34. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo
35. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
36. MDM2-master regulator of the p53 tumor suppressor protein
37. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
38. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice
39. Targeted disruption of Bcl-2 alpha beta in mice: Occurrence of gray hair, polycystic kidney disease, and lymphocytopenia
40. c-Myc and apoptosis
41. Selective regulation of Bcl-XL by a Jak kinase-dependent pathway is bypassed in murine hematopoietic malignancies
42. Infrequent bax gene mutations in B-cell lymphomas
43. Prolongation of ovarian life span into advanced chronological age by Bax- deficiency
44. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest
45. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype
46. BCL-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy
47. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and downregulated by wild-type p53
48. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein
49. Rescue of defective mitogenic signaling by D-type cyclins
50. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
51. Tumor surveillance via the ARF-p53 pathway
52. Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: Reduction in protective apoptotic response at the preneoplastic stage
53. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2
54. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2
55. p19(arf) stabilizes p53 by blocking nucleocytoplasmic shuttling of Mdm2
56. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c- myc to immortalize pre-B cells
57. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair
58. p53-independent functions of the p19(ARF) tumor suppressor
59. Nucleolar ARF sequesters Mdm2 and activates p53
60. JunD protects cells from p53-dependent senescence and apoptosis
61. The p53-mdm-2 autoregulatory feedback loop
62. Bax suppresses tumorigenesis and stimulates apoptosis in vivo
63. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization